This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
| Feature | NADIM |
|---|---|
| Condition | Non Small Cell Lung Cancer |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | Fundación GECP |
| Status | Active, not recruiting |
2. Clinical Question
Population
Patients with non small cell lung cancer.
Intervention
Paclitaxel, carboplatin, and nivolumab.
Comparator
Chemotherapy alone.
Primary Question
Whether chemo-immunotherapy produces a different pathological complete response compared with chemotherapy alone.
3. Trial Design
Randomization
The registry describes a randomized, parallel, two-arm phase 2 treatment study.
Study Size
The planned enrollment is 90 participants.
4. Endpoints
| Endpoint | Registry Definition |
|---|---|
| Pathological complete response (pCR) | Absence of residual tumor in lung and lymph nodes in patients treated with chemo-immunotherapy versus patients treated with chemotherapy alone. |
| Time frame | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 45 months. |
5. Planned Analysis
The registry identifies pathological complete response as the primary endpoint but does not report posted statistical analyses or numerical efficacy results on ClinicalTrials.gov.
A pathological complete response endpoint is generally analyzed by comparing response proportions between randomized groups. Depending on the prespecified statistical analysis plan, methods may include estimation of response rates, confidence intervals, and hypothesis testing for the difference between treatment groups.
6. Statistical Methodology
Binary endpoint analysis
Pathological complete response is a binary outcome: each participant is classified according to whether the defined response criterion is achieved. The statistical comparison focuses on differences in response probability between randomized groups.
Response proportion
The observed response rate is calculated as the number of participants meeting the response definition divided by the number evaluated.
Randomization and causal interpretation
Randomization is designed to create comparable treatment groups at baseline. The randomized comparison allows differences in outcomes to be interpreted as differences associated with assignment to the study interventions, subject to the assumptions and conduct of the trial.
7. Statistical Methods Explained
Why is pathological complete response analyzed as a proportion?
Because pCR represents whether residual tumor is absent or present, it is naturally summarized as the percentage of patients achieving the endpoint in each arm.
What does a treatment-group comparison estimate?
A comparison of response proportions estimates how frequently the endpoint occurred in each randomized group and the uncertainty around the difference.
Why does randomization matter?
Randomization helps separate treatment effects from differences in patient characteristics that could otherwise influence response.
Why are confidence intervals important?
A confidence interval describes uncertainty around an estimated treatment difference. It does not describe outcomes for every individual patient.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses or efficacy estimates.
- The registry does not report subgroup analyses, baseline characteristics, safety results by arm, or interim analysis details.
- Phase 2 randomized studies generally provide estimates of treatment effects with greater uncertainty than larger confirmatory trials.
9. Why This Trial Matters Statistically
| Concept | Application |
|---|---|
| Randomization | Comparison of two treatment strategies. |
| Binary endpoints | Pathological complete response is measured as an event/non-event outcome. |
| Comparative inference | Treatment groups are compared using statistical estimates and uncertainty measures. |
| Clinical trial design | Parallel-arm phase 2 methodology. |